| HOME >> MEDICINE >> TECHNOLOGY |
5 Williams KV, Kelley De. Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes. Diabetes Obes Metab 2000; 2:121–29
6 Wing RR et al. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147:1749–53
7 de Leiva A. What are the benefits of moderate weight loss? Exp Clin Endocrinol Diabetes 1998; 106:10–13
8 Case CC et al. Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab 2002; 4:407–14
9 Krebs JD et al. Changes in risk factors for cardiovascular disease with body fat loss in obese woman. Diabetes Obes Metab 2002; 4:379–87
10 Philis-Tsimikas A et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006; 28(10):1569–81
11 Hermansen K et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29(6):1269–74
12 Rosenstock J et al. Insulin Detemir Added to Oral Anti-Diabetic Drugs in Type 2 Diabetes Provides Glycemic Control Comparable to Insulin Glargine with Less Weight Gain. Diabetes 2006; 55:A132
13 Russell-Jones D et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus regimen. Clin Ther 2004; 26(5):724–36
14 Vague P et al. Insulin detemir is associated with more predictable glycaemic control and reduced risk of hypoglycaemia than NPH insulin in patients with type 1 diabetes on a basal bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26(3):590–96
15 De Leeuw I et al. Insu
'"/>